Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective To develop and validate a diagnostic score that assists in discriminating primary hemophagocytic lymphohistiocytosis (pHLH) from macrophage activation syndrome (MAS) related to systemic juvenile idiopathic arthritis. Study design The clinical, laboratory, and histopathologic features of 362 patients with MAS and 258 patients with pHLH were collected in a multinational collaborative study. Eighty percent of the population was assessed to develop the score and the remaining 20% constituted the validation sample. Variables that entered the best fitted model of logistic regression were assigned a score, based on their statistical weight. The MAS/HLH (MH) score was made up with the individual scores of selected variables. The cutoff in the MH score that discriminated pHLH from MAS best was calculated by means of receiver operating characteristic curve analysis. Score performance was examined in both developmental and validation samples. Results Six variables composed the MH score: age at onset, neutrophil count, fibrinogen, splenomegaly, platelet count, and hemoglobin. The MH score ranged from 0 to 123, and its median value was 97 (1st-3rd quartile 75-123) and 12 (1st-3rd quartile 11-34) in pHLH and MAS, respectively. The probability of a diagnosis of pHLH ranged from <1% for a score of <11 to >99% for a score of ≥123. A cutoff value of ≥60 revealed the best performance in discriminating pHLH from MAS. Conclusion The MH score is a powerful tool that may aid practitioners to identify patients who are more likely to have pHLH and, thus, could be prioritized for functional and genetic testing.

Original languageEnglish (US)
Pages (from-to)72-78.e3
JournalJournal of Pediatrics
Volume189
DOIs
StatePublished - Oct 1 2017

Fingerprint

Macrophage Activation Syndrome
Hemophagocytic Lymphohistiocytosis
Juvenile Arthritis
Splenomegaly
Genetic Testing
Platelet Count
Age of Onset
ROC Curve
Fibrinogen
Hemoglobins
Neutrophils
Logistic Models
Weights and Measures

Keywords

  • diagnostic score
  • hemophagocytic syndrome
  • macrophage activation syndrome
  • primary hemophagocytic lymphohistiocytosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society (2017). Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 189, 72-78.e3. https://doi.org/10.1016/j.jpeds.2017.06.005

Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. / Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society.

In: Journal of Pediatrics, Vol. 189, 01.10.2017, p. 72-78.e3.

Research output: Contribution to journalArticle

Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society 2017, 'Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome', Journal of Pediatrics, vol. 189, pp. 72-78.e3. https://doi.org/10.1016/j.jpeds.2017.06.005
Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics. 2017 Oct 1;189:72-78.e3. https://doi.org/10.1016/j.jpeds.2017.06.005
Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society. / Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. In: Journal of Pediatrics. 2017 ; Vol. 189. pp. 72-78.e3.
@article{11f119603bad45c596fd7822e0be859e,
title = "Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome",
abstract = "Objective To develop and validate a diagnostic score that assists in discriminating primary hemophagocytic lymphohistiocytosis (pHLH) from macrophage activation syndrome (MAS) related to systemic juvenile idiopathic arthritis. Study design The clinical, laboratory, and histopathologic features of 362 patients with MAS and 258 patients with pHLH were collected in a multinational collaborative study. Eighty percent of the population was assessed to develop the score and the remaining 20{\%} constituted the validation sample. Variables that entered the best fitted model of logistic regression were assigned a score, based on their statistical weight. The MAS/HLH (MH) score was made up with the individual scores of selected variables. The cutoff in the MH score that discriminated pHLH from MAS best was calculated by means of receiver operating characteristic curve analysis. Score performance was examined in both developmental and validation samples. Results Six variables composed the MH score: age at onset, neutrophil count, fibrinogen, splenomegaly, platelet count, and hemoglobin. The MH score ranged from 0 to 123, and its median value was 97 (1st-3rd quartile 75-123) and 12 (1st-3rd quartile 11-34) in pHLH and MAS, respectively. The probability of a diagnosis of pHLH ranged from <1{\%} for a score of <11 to >99{\%} for a score of ≥123. A cutoff value of ≥60 revealed the best performance in discriminating pHLH from MAS. Conclusion The MH score is a powerful tool that may aid practitioners to identify patients who are more likely to have pHLH and, thus, could be prioritized for functional and genetic testing.",
keywords = "diagnostic score, hemophagocytic syndrome, macrophage activation syndrome, primary hemophagocytic lymphohistiocytosis",
author = "{Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society} and Francesca Minoia and Francesca Bovis and Sergio Dav{\`i} and Antonella Insalaco and Kai Lehmberg and Susan Shenoi and Sheila Weitzman and Graciela Espada and Gao, {Yi Jin} and Jordi Anton and Toshiyuki Kitoh and Ozgur Kasapcopur and Helga Sanner and Rosa Merino and Itziar Astigarraga and Maria Alessio and Michael Jeng and Vyacheslav Chasnyk and Nichols, {Kim E.} and Zeng Huasong and Caifeng Li and Concetta Micalizzi and Nicolino Ruperto and Alberto Martini and Cron, {Randy Q.} and Angelo Ravelli and Horne, {Anna Carin} and Mario Abinun and Amita Aggarwal and Jonathan Akikusa and Sulaiman Al-Mayouf and Maria Alessio and Jordi Anton and Apaz, {Maria Teresa} and Itziar Astigarraga and Tadej Avcin and Ayaz, {Nuray Aktay} and Patrizia Barone and Bianca Bica and Isabel Bolt and Francesca Bovis and Luciana Breda and Vyacheslav Chasnyk and Rolando Cimaz and Fabrizia Corona and Cron, {Randy Q.} and Ruben Cuttica and Sergio Dav{\`i} and Zane Davidsone and Ilowite, {Norman Todd}",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.jpeds.2017.06.005",
language = "English (US)",
volume = "189",
pages = "72--78.e3",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

AU - Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society

AU - Minoia, Francesca

AU - Bovis, Francesca

AU - Davì, Sergio

AU - Insalaco, Antonella

AU - Lehmberg, Kai

AU - Shenoi, Susan

AU - Weitzman, Sheila

AU - Espada, Graciela

AU - Gao, Yi Jin

AU - Anton, Jordi

AU - Kitoh, Toshiyuki

AU - Kasapcopur, Ozgur

AU - Sanner, Helga

AU - Merino, Rosa

AU - Astigarraga, Itziar

AU - Alessio, Maria

AU - Jeng, Michael

AU - Chasnyk, Vyacheslav

AU - Nichols, Kim E.

AU - Huasong, Zeng

AU - Li, Caifeng

AU - Micalizzi, Concetta

AU - Ruperto, Nicolino

AU - Martini, Alberto

AU - Cron, Randy Q.

AU - Ravelli, Angelo

AU - Horne, Anna Carin

AU - Abinun, Mario

AU - Aggarwal, Amita

AU - Akikusa, Jonathan

AU - Al-Mayouf, Sulaiman

AU - Alessio, Maria

AU - Anton, Jordi

AU - Apaz, Maria Teresa

AU - Astigarraga, Itziar

AU - Avcin, Tadej

AU - Ayaz, Nuray Aktay

AU - Barone, Patrizia

AU - Bica, Bianca

AU - Bolt, Isabel

AU - Bovis, Francesca

AU - Breda, Luciana

AU - Chasnyk, Vyacheslav

AU - Cimaz, Rolando

AU - Corona, Fabrizia

AU - Cron, Randy Q.

AU - Cuttica, Ruben

AU - Davì, Sergio

AU - Davidsone, Zane

AU - Ilowite, Norman Todd

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Objective To develop and validate a diagnostic score that assists in discriminating primary hemophagocytic lymphohistiocytosis (pHLH) from macrophage activation syndrome (MAS) related to systemic juvenile idiopathic arthritis. Study design The clinical, laboratory, and histopathologic features of 362 patients with MAS and 258 patients with pHLH were collected in a multinational collaborative study. Eighty percent of the population was assessed to develop the score and the remaining 20% constituted the validation sample. Variables that entered the best fitted model of logistic regression were assigned a score, based on their statistical weight. The MAS/HLH (MH) score was made up with the individual scores of selected variables. The cutoff in the MH score that discriminated pHLH from MAS best was calculated by means of receiver operating characteristic curve analysis. Score performance was examined in both developmental and validation samples. Results Six variables composed the MH score: age at onset, neutrophil count, fibrinogen, splenomegaly, platelet count, and hemoglobin. The MH score ranged from 0 to 123, and its median value was 97 (1st-3rd quartile 75-123) and 12 (1st-3rd quartile 11-34) in pHLH and MAS, respectively. The probability of a diagnosis of pHLH ranged from <1% for a score of <11 to >99% for a score of ≥123. A cutoff value of ≥60 revealed the best performance in discriminating pHLH from MAS. Conclusion The MH score is a powerful tool that may aid practitioners to identify patients who are more likely to have pHLH and, thus, could be prioritized for functional and genetic testing.

AB - Objective To develop and validate a diagnostic score that assists in discriminating primary hemophagocytic lymphohistiocytosis (pHLH) from macrophage activation syndrome (MAS) related to systemic juvenile idiopathic arthritis. Study design The clinical, laboratory, and histopathologic features of 362 patients with MAS and 258 patients with pHLH were collected in a multinational collaborative study. Eighty percent of the population was assessed to develop the score and the remaining 20% constituted the validation sample. Variables that entered the best fitted model of logistic regression were assigned a score, based on their statistical weight. The MAS/HLH (MH) score was made up with the individual scores of selected variables. The cutoff in the MH score that discriminated pHLH from MAS best was calculated by means of receiver operating characteristic curve analysis. Score performance was examined in both developmental and validation samples. Results Six variables composed the MH score: age at onset, neutrophil count, fibrinogen, splenomegaly, platelet count, and hemoglobin. The MH score ranged from 0 to 123, and its median value was 97 (1st-3rd quartile 75-123) and 12 (1st-3rd quartile 11-34) in pHLH and MAS, respectively. The probability of a diagnosis of pHLH ranged from <1% for a score of <11 to >99% for a score of ≥123. A cutoff value of ≥60 revealed the best performance in discriminating pHLH from MAS. Conclusion The MH score is a powerful tool that may aid practitioners to identify patients who are more likely to have pHLH and, thus, could be prioritized for functional and genetic testing.

KW - diagnostic score

KW - hemophagocytic syndrome

KW - macrophage activation syndrome

KW - primary hemophagocytic lymphohistiocytosis

UR - http://www.scopus.com/inward/record.url?scp=85028299738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028299738&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2017.06.005

DO - 10.1016/j.jpeds.2017.06.005

M3 - Article

C2 - 28807357

AN - SCOPUS:85028299738

VL - 189

SP - 72-78.e3

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

ER -